Brief: Seres Therapeutics FY EPS USD -0.89
05/03/2024 12:00
Mar 05 (Reuters) - Seres Therapeutics FY collaboration revenue USD 126.325 million. * FY operating expenses USD 234.308 million * FY operating income USD -107.983 million * FY net income USD -113.724 million
Recent news on Seres Therapeutics
See all newsChinese automakers make tech-led pitch for Europe's premium car market
Brief: Seres Therapeutics - May Offer Up To $300 Million Of Securities
Seres Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Seres Therapeutics Q2 net income turns positive on VOWST sale gain
Brief: Seres Therapeutics Q2 EPS USD 0.47